Lupin has informed about submission of a Press Release as regards completion of an inspection carried out by the US FDA at the Company's Pithampur (Unit-I) facility. The inspection was carried out between February 3, 2020 and February 11, 2020. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company's filings submitted to BSE.